Matthew B. Murphy

This profile gathers the share dealings of Matthew B. Murphy in Nautilus Biotechnology, Inc., where the filings describe the role as board member. In total, 4 filings cover trades dated from 13 August 2021 to 4 September 2025.

Every open-market trade on record is a purchase: 3 purchases worth €50k, and no sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 1 share grant. Since January 2025: 1 purchase and no sales on the market.

A typical purchase (the median) is worth €11k. On 1 out of 3 purchases, another insider of the same company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

On 5 September 2025 came the latest disclosure, an open-market purchase for €11k in Nautilus Biotechnology, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.